Health & Biotech
Exopharm (ASX: EX1) has changed its name to Tryptamine Therapeutics - TYP (ASX: TYP).
Below are the previous articles from Exopharm (ASX: EX1):
RELATED STOCKHEAD STORIES
Health & Biotech
Exopharm and Astellas team up for exosomes evaluation
Health & Biotech
Exopharm secures US patent for exosomes purification technology
Health & Biotech
ASX Health Stocks: Lumos is ready to seek regulatory approval for its COVID-19 rapid antigen test
News
Market Highlights and 5 ASX Small Caps to watch on Wednesday
Health & Biotech
Exopharm shares soar 12pc on Q1 update as LEAP tech promises to advance wide range of medicines
Health & Biotech
Exopharm appoints two key executives as it transitions into a global exosomes company
Health & Biotech
Exopharm signs deal with Japanese chemical company as LEAP tech promise to accelerate new cancer-beating research
News
ASX Health Stocks: Medical imaging player Resonance Health leads the pack with FY21 revenue increase
Stockhead TV
V-Con: Talking medical innovations and breakthrough treatments with ASX biotechs
Health & Biotech
Exopharm takes major step forward in global strategy with approval for its first national patent
Health & Biotech
$12m capital raising puts Exopharm in strong position to negotiate new partnerships
Health & Biotech
Pitt Street Research says Exopharm worth up to $4.71 a share
Health & Biotech
Exopharm’s great LEAP forward gets an all-clear cheers from Finland’s Red Cross service
News
Market highlights and 5 ASX small caps to watch on Tuesday
News
Closing Bell: Today’s biggest small cap movers on the ASX
Health & Biotech
Bard1 caps off 600pc+ in 6 weeks proving it can detect another type of cancer
Health & Biotech
